Ignite Creation Date:
2025-12-24 @ 10:02 PM
Ignite Modification Date:
2026-01-05 @ 6:09 PM
Study NCT ID:
NCT00334932
Status:
UNKNOWN
Last Update Posted:
2014-01-10
First Post:
2006-06-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Sponsor:
Herbert Irving Comprehensive Cancer Center
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
CDR0000471769
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |